Quest for selectivity in inhibition of matrix metalloproteinases

Current Topics in Medicinal Chemistry

Volumn 4, Issue 12, 2004, Pages 1227-1238

  Brown, Stephen ^a   Meroueh, Samy O ^a   Fridman, Rafael ^b   Mobashery, Shahriar ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; COLLAGENASE 3; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MACROCYCLIC COMPOUND; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PHOSPHONIC ACID DERIVATIVE; STROMELYSIN; THIOL;

BINDING SITE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; IC 50; INFLAMMATION; METASTASIS; NEUROLOGIC DISEASE; PROTEIN FUNCTION; REVIEW;

ANIMALS; DRUG DESIGN; HUMANS; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; PROTEASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 4444347179     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387854     Document Type: Review

References (98)

1. Gross, J.; Lapiere, C.M. Collagenolytic activity in amphibian tissues: a tissue-culture assay. P. Natl. Acad. Sci. USA 1962, 48, 1014-1022.
2. Bauer, E.A.; Eisen, A.Z.; Jeffrey, J.J. Immunologic relation of a purified human skin collagenase to other human and animal collagenases. Biochim. Biophys. Acta 1970, 206, 152-160.
3. Pei, D. CA-MMP: a matrix metalloproteinase with a novel cysteine array, but without the classic cysteine switch. FEBS Lett. 1999, 457, 262-270.
4. Pei, D.; Kang, T.; Qi, H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem. 2000, 275, 33988-33997.
5. Velasco, G.; Pendas, A.M.; Fueyo, A.; Knauper, V.; Murphy, G.; Lopez-Otin, C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 1999, 274, 4570-4576.
6. Parks, W.C.; Shapiro, S.D. Matrix metalloproteinases in lung biology. Respir. Res. 2001, 2, 10-19.
7. McCawley, L.J.; Matrisian, L.M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 2001, 13, 534-540.
8. Wilson, C.L.; Ouellette, A.J.; Satchell, D.P.; Ayabe, T.; Lopez-Boado, Y.S.; Stratman, J.L.; Hultgren, S.J.; Matrisian, L.M.; Parks, W.C. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999, 286, 113-117.
9. Suzuki, M.; Raab, G.; Moses, M.A.; Fernandez, C.A.; Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 1997, 272, 31730-31737.
10. Haro, H.; Crawford, H.C.; Fingleton, B.; Shinomiya, K.; Spengler, D.M.; Matrisian, L.M. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J. Clin. Invest. 2000, 105, 143-150.
11. Gearing, A.J.; Beckett, P.; Christodoulou, M.; Churchill, M.; Clements, J.; Davidson, A.H.; Drummond, A.H.; Galloway, W.A.; Gilbert, R.; Gordon, J.L. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370, 555-557.
12. McGeehan, G.M.; Becherer, J.D.; Bast, R.C., Jr.; Boyer, C.M.; Champion, B.; Connolly, K.M.; Conway, J.G.; Furdon, P.; Karp, S.; Kidao, S. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994, 370, 558-561.
13. Manes, S.; Mira, E.; Barbacid, M.M.; Cipres, A.; Fernandez-Resa, P.; Buesa, J.M.; Merida, I.; Aracil, M.; Marquez, G.; Martinez, A.C. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem. 1997, 272, 25706-25712.
14. Gu, Z.Z.; Kaul, M.; Yan, B.X.; Kridel, S.J.; Cui, J.K.; Strongin, A.; Smith, J.W.; Liddington, R.C.; Lipton, S.A. S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death. Science 2002, 297, 1186-1190.
15. Okamoto, T.; Akaike, T.; Sawa, T.; Miyamoto, Y.; van der Vliet, A.; Maeda, H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 2001, 276, 29596-29602.
16. Brenneisen, P.; Wenk, J.; Klotz, L.O.; Wlaschek, M.; Briviba, K.; Krieg, T.; Sies, H.; Scharffetter-Kochanek, K. Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. J. Biol. Chem. 1998, 273, 5279-5287.
17. Yoo, H.G.; Shin, B.A.; Park, J.S.; Lee, K.H.; Chay, K.O.; Yang, S.Y.; Ahn, B.W.; Jung, Y.D. IL-1.beta. induces MMP-9 via reactive oxygen species and NF-.kappa.B in murine macrophage RAW 264.7 cells. Biochem. Bioph. Res. Co. 2002, 298, 251-256.
18. Shah, P.K.; Galis, Z.S. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation 2001, 104, 1878-1880.
19. Lo, Y.Y.C.; Wong, J.M.S.; Cheung, W.-F.; Cruz, T.F., Reactive oxygen species and the regulation of metalloproteinase expression, in Free Radicals and Inflammation. 2000, Birkhauser Verlag: Basel (Switzerland). p. 133-153.
20. Van Wart, H.E.; Birkedal-Hansen, H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. P. Natl. Acad. Sci. USA 1990, 87, 5578-5582.
21. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Tryggvason, K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. P. Natl. Acad. Sci. USA 2002, 99, 7414-7419.
22. Kotra, L.P.; Cross, J.B.; Shimura, Y.; Fridman, R.; Schlegel, H.B.; Mobashery, S. Insight into the complex and dynamic process of activation of matrix metalloproteinases. J. Am. Chem. Soc. 2001, 123, 3108-3113.
23. Egebald, M.; Werb, Z. New Functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2002, 2, 161-173.
24. Michaelides, M.R.; Curtin, M.L. Recent advances in matrix metalloproteinase inhibitors research. Curr. Pharm. Design 1999, 5, 787-819.
25. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
26. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001, 8, 425-474.
27. Bayer Pharmaceuticals, Bayer halts clinical trials evaluating MMP1, 1999, http://bayerusa.com/news/co0221.asp
28. Agouron, Pfizer discontinues phase 3 trials of prinomastat in advanced cancers but continues multiple phase 2 trials., 2000, http://agouron.com/Pages/press_releases/pr080400.html
29. British Biotech, Marimastat update, 2001, http://www.britbio.com/news/173,183analysis.pdf
30. Zucker, S.; Cao, J.; Chen, W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000, 19, 6642-6650.
31. Brown, P.D. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin. Inv. Drug. 2000, 9, 2167-2177.
32. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2392.
33. Browner, M.F.; Smith, W.W.; Castelhano, A.L. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995, 34, 6602-6610.
34. Moy, F.J.; Chanda, P.K.; Cosmi, S.; Pisano, M.R.; Urbano, C.; Wilhelm, J.; Powers, R. High-resolution solution structure of the inhibitor-free catalytic fragment of human fibroblast collagenase determined by multidimensional NMR. Biochemistry 1998, 37, 1495-1504.
35. Chen, L.; Rydel, T.J.; Gu, F.; Dunaway, C.M.; Pikul, S.; Dunham, K.M.; Barnett, B.L. Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes. J. Mol. Biol. 1999, 293, 545-557.
36. Nar, H.; Werle, K.; Bauer, M.M.; Dollinger, H.; Jung, B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J. Mol. Biol. 2001, 312, 743-751.
37. Lang, R.; Kocourek, A.; Braun, M.; Tschesche, H.; Huber, R.; Bode, W.; Maskos, K. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J. Mol. Biol. 2001, 312, 731-742.
38. Libson, A.M.; Gittis, A.G.; Collier, I.E.; Marmer, B.L.; Goldberg, G.I.; Lattman, E.E. Crystal structure of the haemopexin-like C-terminal domain of gelatinase A. Nat. Struct. Biol. 1995, 2, 938-942.
39. Cha, H.; Kopetzki, E.; Huber, R.; Lanzendorfer, M.; Brandstetter, H. Structural basis of the adaptive molecular recognition by MMP9. J. Mol. Biol. 2002, 320, 1065-1079.
40. Gomis-Ruth, F.X.; Gohlke, U.; Betz, M.; Knauper, V.; Murphy, G.; Lopez-Otin, C.; Bode, W. The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. J. Mol. Biol. 1996, 264, 556-566.
41. Gehrmann, M.; Briknarova, K.; Banyai, L.; Patthy, L.; Llinas, M. The col-1 module of human matrix metalloproteinase-2 (MMP-2): structural/functional relatedness between gelatin-binding fibronectin type II modules and lysine-binding kringle domains. Biol. Chem. 2002, 383, 137-148.
42. Li, J.; Brick, P.; O'Hare, M.C.; Skarzynski, T.; Lloyd, L.F.; Curry, V.A.; Clark, I.M.; Bigg, H.F.; Hazleman, B.L.; Cawston, T.E.; et al. Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. Structure 1995, 3, 541-549.
43. Elkins, P.A.; Ho, Y.S.; Smith, W.W.; Janson, C.A.; D'Alessio, K.J.; McQueney, M.S.; Cummings, M.D.; Romanic, A.M. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr. D 2002, 58, 1182-1192.
44. Bode, W.; Fernandez-Catalan, C.; Tschesche, H.; Grams, F.; Nagase, H.; Maskos, K. Structural properties of matrix metalloproteinases. Cell. Mol. Life Sci. 1999, 55, 639-652.
45. Gomis-Ruth, F.X.; Maskos, K.; Betz, M.; Bergner, A.; Huber, R.; Suzuki, K.; Yoshida, N.; Nagase, H.; Brew, K.; Bourenkov, G.P.; Bartunik, H.; Bode, W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997, 389, 77-81.
46. Borkakoti, N. Structural studies of matrix metalloproteinases. J. Mol. Med. 2000, 78, 261-268.
47. Bode, W.; Gomis-Ruth, F.X.; Stockler, W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett. 1993, 331, 134-140.
48. Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F.X.; McKay, D.B.; Bode, W. The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci. 1995, 4, 823-840.
49. Kotra, L.P.; Zhang, L.; Fridman, R.; Orlando, R.; Mobashery, S. N-Glycosylation pattern of the zymogenic form of human matrix metalloproteinase-9. Bioorg. Chem. 2002, 30, 356-370.
50. Rudd, P.M.; Mattu, T.S.; Masure, S.; Bratt, T.; van den Steen, P.E.; Wormald, M.R.; Kuester, B.; Harvey, D.J.; Borregaard, N.; Van Damme, J.; Dwek, R.A.; Opdenakker, G. Glycosylation of Natural Human Neutrophil Gelatinase B and Neutrophil Gelatinase B-Associated Lipocalin. Biochemistry 1999, 38, 13937-13950.
51. Mattu, T.S.; Royle, L.; Langridge, J.; Wormald, M.R.; Van den Steen, P.E.; Van Damme, J.; Opdenakker, G.; Harvey, D.J.; Dwek, R.A.; Rudd, P.M. O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme. Biochemistry 2000, 39, 15695-15704.
52. BD Biosciences, Matrix Metalloproteinases, Spring 2001, http://www.bdbiosciences.com/cgi-bin/literature/ archive?type=6&brand=4
53. Nagase, H.; Woessner, J.F., Jr. Matrix metalloproteinases. J. Biol. Chem. 1999, 274, 21491-21494.
54. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58, 1048-1051.
55. Bullard, K.M.; Lund, L.; Mudgett, J.S.; Mellin, T.N.; Hunt, T.K.; Murphy, B.; Ronan, J.; Werb, Z.; Banda, M.J. Impaired wound contraction in stromelysin-1-deficient mice. Ann. Surg. 1999, 230, 260-265.
56. Wang, M.; Qin, X.; Mudgett, J.S.; Ferguson, T.A.; Senior, R.M.; Welgus, H.G. Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. P. Natl. Acad. Sci. USA 1999, 96, 6885-6889.
57. Wilson, C.L.; Heppner, K.J.; Labosky, P.A.; Hogan, B.L.; Matrisian, L.M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. P. Natl. Acad. Sci. USA 1997, 94, 1402-1407.
58. Coussens, L.M.; Tinkle, C.L.; Hanahan, D.; Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103, 481-490.
59. Takeha, S.; Fujiyama, Y.; Bamba, T.; Sorsa, T.; Nagura, H.; Ohtani, H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn. J. Cancer Res. 1997, 88, 72-81.
60. Pozzi, A.; LeVine, W.F.; Gardner, H.A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002, 21, 272-281.
61. Vu, T.H.; Shipley, J.M.; Bergers, G.; Berger, J.E.; Helms, J.A.; Hanahan, D.; Shapiro, S.D.; Senior, R.M.; Werb, Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93, 411-422.
62. Betsuyaku, T.; Fukuda, Y.; Parks, W.C.; Shipley, J.M.; Senior, R.M. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 2000, 157, 525-535.
63. Heymans, S.; Luttun, A.; Nuyens, D.; Theilmeier, G.; Creemers, E.; Moons, L.; Dyspersin, G.D.; Cleutjens, J.P.; Shipley, M.; Angellilo, A.; Levi, M.; Nube, O.; Baker, A.; Keshet, E.; Lupu, F.; Herbert, J.M.; Smits, J.F.; Shapiro, S.D.; Baes, M.; Borgers, M.; Collen, D.; Daemen, M.J.; Carmeliet, P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 1999, 5, 1135-1142.
64. Knowlton, K.U.; Chien, K.R. Inflammatory pathways and cardiac repair: the affliction of infarction. Nat. Med. 1999, 5, 1122-1123.
65. Masson, R.; Lefebvre, O.; Noel, A.; Fahime, M.E.; Chenard, M.P.; Wendling, C.; Kebers, F.; LeMeur, M.; Dierich, A.; Foidart, J.M.; Basset, P.; Rio, M.C. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelia cell malignancy. J. Cell. Biol. 1998, 140, 1535-1541.
66. Lijnen, H.R.; Van Hoef, B.; Vanlinthout, I.; Verstreken, M.; Rio, M.C.; Collen, D. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscl. Throm. Vas. 1999, 19, 2863-2870.
67. Hautamaki, R.D.; Kobayashi, D.K.; Senior, R.M.; Shapiro, S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277, 2002-2004.
68. Foronjy, R.; D'Armiento, J. The role of collagenase in emphysema. Respir. Res. 2001, 2, 348-352.
69. Dalal, S.; Imai, K.; Mercer, B.; Okada, Y.; Chada, K.; D'Armiento, J.M. A role for collagenase (Matrix metalloproteinase-1) in pulmonary emphysema. Chest 2000, 117, 227S-228S.
70. Shipley, J.M.; Wesselschmidt, R.L.; Kobayashi, D.K.; Ley, T.J.; Shapiro, S.D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. P. Natl. Acad. Sci. USA 1996, 93, 3942-3946.
71. Holmbeck, K.; Bianco, P.; Caterina, J.; Yamada, S.; Kromer, M.; Kuznetsov, S.A.; Mankani, M.; Robey, P.G.; Poole, A.R.; Pidoux, I.; Ward, J.M.; Birkedal-Hansen, H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99, 81-92.
72. Zhou, Z.; Apte, S.S.; Soininen, R.; Cao, R.; Baaklini, G.Y.; Rauser, R.W.; Wang, J.; Cao, Y.; Tryggvason, K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. P. Natl. Acad. Sci. USA 2000, 97, 4052-4057.
73. Levy, D.E.; Lapierre, F.; Liang, W.; Ye, W.; Lange, C.W.; Li, X.; Grobelny, D.; Casabonne, M.; Tyrrell, D.; Holme, K.; Nadzan, A.; Galardy, R.E. Matrix metalloproteinase inhibitors: a structure-activity study. J. Med. Chem. 1998, 41, 199-223.
74. O'Brien, P.M.; Ortwine, D.F.; Pavlovsky, A.G.; Picard, J.A.; Sliskovic, D.R.; Roth, B.D.; Dyer, R.D.; Johnson, L.L.; Man, C.; Hallak, H. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J. Med. Chem. 2000, 43, 156-166.
75. Matter, H.; Schwab, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Schudok, M.; Thorwart, W.; Schreuder, H.; Brachvogel, V.; Lonze, P.; Weithmann, K.U. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. J. Med. Chem. 1999, 42, 1908-1920.
76. Tamaki, K.; Tanzawa, K.; Kurihara, S.; Oikawa, T.; Monma, S.; Shimada, K.; Sugimura, Y. Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Chem. Pharm. Bull. 1995, 43, 1883-1893.
77. Vassiliou, S.; Mucha, A.; Cuniasse, P.; Georgiadis, D.; Lucet-Levannier, K.; Beau, F.; Kannan, R.; Murphy, G.; Knauper, V.; Rio, M.C.; Basset, P.; Yiotakis, A.; Dive, V. Phosphinic pseudotripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. J. Med. Chem. 1999, 42, 2610-2620.
78. Li, Y.C.; Zhang, X.; Melton, R.; Ganu, V.; Gonnella, N.C. Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry 1998, 37, 14048-14056.
79. Grams, F.; Reinemer, P.; Powers, J.C.; Kleine, T.; Pieper, M.; Tschesche, H.; Huber, R.; Bode, W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur. J. Biochem. 1995, 228, 830-841.
80. Borkakoti, N.; Winkler, F.K.; Williams, D.H.; D'Arcy, A.; Broadhurst, M.J.; Brown, P.A.; Johnson, W.H.; Murray, E.J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat. Struct. Biol. 1994, 1, 106-110.
81. Moy, F.J.; Chanda, P.K.; Chen, J.; Cosmi, S.; Edris, W.; Levin, J.I.; Rush, T.S.; Wilhelm, J.; Powers, R. Impact of mobility on structure-based drug design for the MMPs. J. Am. Chem. Soc. 2002, 124, 12658-12659.
82. Terp, G.E.; Cruciani, G.; Christensen, I.T.; Jorgensen, F.S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem. 2002, 45, 2675-2684.
83. Brown, S.; Bernardo, M.M.; Li, Z.-H.; Kotra, L.P.; Tanaka, Y.; Fridman, R.; Mobashery, S. Potent and Selective Mechanism-Based Inhibition of Gelatinases. J. Am. Chem. Soc. 2000, 122, 6799-6800.
84. Cherney, R.J.; Wang, L.; Meyer, D.T.; Xue, C.B.; Wasserman, Z.R.; Hardman, K.D.; Welch, P.K.; Covington, M.B.; Copeland, R.A.; Arner, E.C.; DeGrado, W.F.; Decicco, C.P. Macrocyclic amino carboxylates as selective MMP-8 inhibitors. J. Med. Chem. 1998, 41, 1749-1751.
85. Sawa, M.; Kondo, H.; Nishimura, S. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom. Bioorg. Med. Chem. Lett. 2002, 12, 581-584.
86. AndrianJara, C.; Ortwine, D.F.; Pavlovsky, A.G.; Roark, W.H., Preparation of Substituted Isophtalic Acid Derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors, PCT Int. Appl. WO 0264080 A2,
87. Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.; Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka T.; Kawada, K.; Sugita, K.; Ohtani, M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 1998, 41, 640-649.
88. Beckett, R.P.; Martin, F.M.; Miller, A.; Todd, R.S.; Whittaker, M., Preparation of Sulfonylaminoalkanediamides and Related Compounds as Matrix Metalloproteinase Inhibitors, PCT Patent Application WO9817655,
89. Bernardo, M.M.; Brown, S.; Li, Z.H.; Fridman, R.; Mobashery, S. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J. Biol. Chem. 2002, 277, 11201-11207.
90. Beckett, R.P.; Miller, A.; Spavold, Z.M.; Whittaker, M. Patent Application WO9633165, 1996. Chem. Abstr. 1997, 126, 18654.
91. O'Brien, P.M.; Sliskovic, D.R.; Roth, B.D.; Ortwine, D.F.; Dyer, R.; Johnson, L.; Hallak, H.; Peterson, J.T.; Bocan, T.M.A. in Poster at XVth EFMC International Symposium on Medicinal Chemistry. 1998. Edinburgh.
92. Betz, M.; Huxley, P.; Davies, S.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis- Ruth, F. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem. 1997, 247, 356-363.
93. Kleifeld, O.; Kotra, L.P.; Gervasi, D.C.; Brown, S.; Bernardo, M.M.; Fridman, R.; Mobashery, S.; Sagi, I. X-ray Absorption Studies of Human Matrix Metalloproteinase-2 (MMP-2) Bound to a Highly Selective Mechanism-based Inhibitor. Comparison with the latent and active forms of the enzyme. J. Biol. Chem. 2001, 276, 17125-17131.
94. Cherney, R.J.; Decicco, C.P.; Nelson, C.R.; Wan, L.; Meyer, D.T.; Hardman, K.D.; Copeland, R.A.; Arner, E.C. Poten Carboxylate Inhibitors of Stromelysin Containing P2′ Piperazic Acids and P1′ Biaryl Moieties. Bioorg. Med. Chem. Lett. 1997, 7, 1757-1762.
95. Betz, M.; Huxley, P.; Davies, S.J.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis-Ruth, F.X. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile, Eur. J. Biochem. 1997, 247, 356-363.
96. Chen, J.M.; Nelson, F.C.; Levin, J.I.; Mobilio, D.; Moy, F.J.; Nilakantan, R.; Zask, A.; Powers, R. Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J. Am. Chem. Soc. 2000, 122, 9648-9654.
97. Adrianjara, C.; Ortwine, D.F.; Pavlovsky, A.G.; Roark, W.H., Preparation of substituted isophtalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors, PCT In. Appl. CODEN: PIXXD2 WO0264080,
98. Kiyama, R.; Tamura, Y.; Watanabe, F.; Tsuzuki, H.; Ohtani, M.; Yodo, M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J. Med. Chem. 1999, 42, 1723-1738.